Outcome following preterm birth.

Preterm birth currently occurs in approximately 12% of pregnancies and appears to be increasing despite improvements in obstetric care. Improvements in neonatal care have led to increased survival, particularly at extreme prematurity, but survival may be associated with significant morbidity. This may be acute, reflecting the difficulties in supporting an individual in a hostile extrauterine environment to which they should not be exposed, or chronic, reflecting disturbances to fragile, immature body systems. Brain, lungs, intestines and eyes are particularly vulnerable and damage may be severe. For some infants the consequences of this damage may be permanent disability and impairment. Despite this, the limited information currently available suggests that adult outcomes may be comparable with those for infants born at term.

The contributions of plasma IGF-I, IGFBP-3 and leptin to growth in extremely premature infants during the first two years.

We determined the contributions of IGF-I, IGFBP-3 and leptin to growth in extremely premature infants over the first two years. Weight (Wt), crown-to heel length (CHL), plasma IGF-I, IGFBP-3 and leptin were measured in infants (gestation 24-33 wk) at birth (n = 54), expected date of delivery (EDD) and 6, 12 and 24 mo post-EDD (n = 29). Area under the curve (AUC) for hormone levels was calculated over 4 periods: birth-EDD, EDD-200 d, EDD-350 d and EDD-700 d. IGFBP-3, but not IGF-I or leptin, on day 1 correlated with birth Wt SD scores (SDS) (r = 0.46, p = 0.002) and CHL SDS (r = 0.41, p = 0.01). Wt SDS at EDD correlated with AUC IGF-I, IGFBP-3 and leptin (birth-EDD), but leptin was the best predictor in multiple regression (r = 0.65, p < 0.0001). Wt at EDD + 700 d correlated with AUC leptin (EDD-700 d) (r = 0.62, p = 0.002). CHL SDS at EDD correlated with AUC IGFBP-3 and leptin (birth-EDD), but IGFBP-3 was the best predictor (r = 0.55, p < 0.0001). CHL at EDD + 700 d correlated with AUC IGF-I and IGFBP-3 (EDD-700 d), but IGFBP-3 was the best predictor (r = 0.47, p = 0.01). Wt and CHL at birth were associated with IGFBP-3 levels in these infants. Wt at EDD and EDD + 700 d was predicted by concurrent leptin output while linear growth at EDD and EDD + 700 d was predicted by IGFBP-3 output.

Adaptation of the Carter method to adjust lumbar spine bone mineral content for age and body size: application to children who were born preterm.

In adults, the Carter method allows the separation of the lumbar spine bone mineral content (BMC) into its constituents; bone volume (BV) and volumetric density (bone mineral apparent density [BMAD]). However, this method is not widely used in pediatric studies and does not account for the effects of body habitus on bone mass. The aims of this study were to modify the Carter method for use in children by developing an approach that adjusts separately for age and body height, and to test whether lumbar spine bone mass is normal in children born who were born preterm. Twenty-five preterm-born children were matched to a term-born child. Lumbar spine bone mass was measured using dual-energy X-ray absorptiometry. The BV and BMAD were calculated. Z-scores based on age and height were calculated. The preterm group had reduced absolute height, weight, BMC, BV, and BMAD, and reduced height, weight, and BMC for their age. The BMC was appropriate for height. The BV was appropriate for age. The BMAD was reduced for age but appropriate for height. In preterm children, the major abnormality at the lumbar spine is a decrease in volumetric density; however, this decrease is proportional with their reduced stature, and we speculate that there is no reduction in the strength of the lumbar spine.

Measurement and the newborn infant.

Measurement of newborn babies is widely regarded as being too inaccurate to justify its regular practice. It is common for infants to be weighed at birth and for no other measurements to be made. Although such assumptions are superficially correct, it is possible to train people to perform accurate measurements and for improved performance to be sustained. Accurate sequential measurements are possible and provide more information than single measurements. Detailed measurements show that postnatal growth may change rapidly and dramatically, particularly in preterm infants. Postnatal growth impairment is common in such infants and may be sustained. Limited evidence suggests that there may be a significant reduction in final stature. Preliminary data also suggest that many preterm infants may also show evidence of alterations in biochemical and physiological variables consistent with early programming and the potential for altered disease susceptibility in adult life.

Perinatal corticosteroids and the developing lung.

A significant number of infants are born prematurely each year, many of whom will develop respiratory disease and require ventilation. A substantial number of these infants will die and many of the survivors will subsequently develop chronic inflammatory lung disease. Administration of corticosteroids to women prior to a premature delivery is associated with a significant reduction in mortality and in the incidence of respiratory distress syndrome and intracranial haemorrhage in their infants once born. Postnatal administration of corticosteroids to the infant who develops chronic lung disease has been widely practised for many years. Recent meta-analyses have suggested that benefit may be limited. Treatment is also associated with a range of different side-effects but it has been assumed that the cost-benefit ratio favoured treatment. Recent evidence of permanent and highly significant long-term adverse effects has questioned the validity of this judgement.